Novel promising functional cell models to study molecular events in metabolic syndrome

Nutritional Therapy and Metabolism

Volumn 30, Issue 1, 2012, Pages 34-41

  Gorenjak, Mario ^a   Skok, Pavel ^b   Cencic, Avrelija ^a  

^a UNIVERSITY OF MARIBOR   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

Functional cell models; Insulin resistance syndrome; Metabolic syndrome; Probiotics; Syndrome x

Indexed keywords

EID: 84867519880     PISSN: 18286232     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
2. Unwin N. The metabolic syndrome. J R Soc Med 2006; 99: 457-62.
3. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551-6.
4. Wen CJ, Lee YS, Lin WY, et al. The metabolic syndrome increases cardiovascular mortality in Taiwanese elderly. Eur J Clin Invest 2008; 38: 469-75.
5. Morales DD, Punzalan FE, Paz-Pacheco E, Sy RG, Duante CA. Metabolic syndrome in the Philippine general population: prevalence and risk for atherosclerotic cardiovascular disease and diabetes mellitus. Diab Vasc Dis Res 2008; 5: 36-43.
6. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-7.
7. Stern MP, Williams K, Gonzales-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676-81.
8. Sundström J, Risérus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332: 878-82.
9. Eberly LE, Prineas R, Cohen JD, et al. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006; 29: 123-30.
10. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
11. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-4.
12. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-6.
13. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care Rev 2001: 24: 683-9.
14. Sowers JR, Fronlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004; 88: 63-82.
15. Reaven GM. Insulin resistance and its consequences. In: LeRoith D, Taylor SI, Olefasky JM, eds. Diabets mellitus: A fundamental and clinical text. Philadelphia: Lippincott, Williams and Wilkins 2004; 899-915.
16. Low Wang C, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004; 53: 2735-40.
17. Brennan AM, Sweenwy L, Mantzoros CS. The metabolic syndrome. In: Brennan AM, Sweenwy L, Mantzoros CS, eds. Contemporary diabetes - Diabetes and exercise. New York: Humana Press, 2009; 69-81.
18. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death. J Am Coll Cardiol 2007; 49: 403-14.
19. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk. J Am Coll Cardiol 2010; 56: 1113-32.
20. Duvnjak L, Duvnjak M. The metabolic syndrome - an ongoing story. J Physiol Pharmacol 2009; 60: 19-24.
21. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad 2010; 86: 131-41.
22. Suganami T, Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol 2010; 88: 1-7.
23. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. Genes and molecules of Lactobacilli supporting probiotic action. Microbiol Mol Biol Rev 2008; 72: 728-64.
24. Marteau P, Seksik P, Jian R. Probiotics and health: new facts and ideas. Curr Opin Biotechnol 2002; 13: 486-9.
25. Ouwehand AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek 2002; 82: 279-89.
26. Sanders ME. Considerations for use of probiotic bacteria to modulate human health. J Nutr 2000; 130: 384S-90S.
27. Mann GV, Spoerry A. Studies of a surfactant and cholesterolemia in the Maasai. Am J Clin Nutr 1974; 27: 464-9.
28. Lye HS, Kuan CY, Ewe JA, Fung WY, Liong MT. The improvement of hypertension by probiotics: effects on cholesterol, diabetes, rennin and phytoestrogens. Int J Mol Sci 2009; 10: 3755-75.
29. Patel AK, Singhania RR, Pandey A, Chincholkar SB. Probiotic bile salt hydrolase: current developments and perspectives. Appl Biochem Biotechnol 2010; 162: 166-80.
30. Ooi LG, Liong MT. Cholesterol-lowering effects of probiotics and prebiotics: a review of in vitro and in vivo findings. Int J Mol Sci 2010: 11: 2499-522
31. Zhang M, Hang X, Fan X, Li D, Yang H. Characterization and selection of Lactobacillus strains for their effect on bile tolerance, taurocholate deconjugation and cholesterol removal. World J Microbiol Biotechnol 2008; 24: 7-14.
32. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr ol removal. World J Microbiol Biotechnol 2008; 24: 7-14.
33. Begley M, Hill C, Gahan CGM. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 2006; 72: 1729-38.
34. Klaver FAM, van der Meer R. The assumed assimilation of cholesterol by lactobacilli and Bifidobacterium bifidum is due to their bile salt deconjugating activity. Appl Environ Microbiol 1993; 59: 1120-4.
35. Gilliland SE, Nelson CR, Maxwell C. Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol 1985; 49: 377-81.
36. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 50: 2374-83.
37. Kalliomaki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008; 87: 534-8.
38. Lundell AC, Adlerberth I, Lindberg E, et al. Increased levels of circulating CD14 but not CD83 in infants are associated with early intestinal colonization with Staphylococcus aureus. Clin Exp Allergy 2007; 37: 62-71.
39. Collado MC, Isolauri E, Laitinen K, Salminen S. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. Am J Clin Nutr 2008; 88: 894-9.
40. Santacruz A, Marcos A, Warnberg J, et al. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity 2009; 17: 1906-15.
41. Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol 2009; 9: 737-43.
42. Medina J, Garcia-Buey L, Fernandez-Salazar LI, MorenoOtero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004; 27: 2057-65.
43. Hakomori S. Tumor malignancy defined by aberrant glycosylation amd sphyngo (glyco) lipid metabolism. Cancer Res 1996; 56: 5309-18.
44. Cencic A, Langerholc T. Functional cell models of the gut and their applications in food microbiology - a review. Int J Food Microbiol 2010; 141: S4-S14.
45. Gradisnik L, Filipic B, Vaureix C, Lefevre F, La Bonnardiere C, Cencic A. Establishment of a functional cell culture model of the pig small intestine. ALTEX, 2006; 23: 94.
46. Cencic A. EU-WP6 Programme PathogenCombat Annual Report, 2006; www.pathogencombat.com.
47. Cencic A. EU-WP6 Programme PathogenCombat Annual Report, 2007; www.pathogencombat.com.
48. Cencic A. Intestinal cell models as alternative to experimental animals in research of food and water born viruses interactions with the host. Oral presentation, 8th International Symposium on Experimental Techniques. Experimental Pathology and Health Sciences 2007, vol 1(1). Faro, Portugal, p 57.
49. Cencic A. EU-WP6 Programme PathogenCombat Annual Report, 2008; www.pathogencombat.com.
50. Cencic A, Gradisnik L, Vaukner T, et al. Alternative to experimental animals - functional cell models with the application in the research of foodborne pathogens in the gut: plenary lecture. International Conference of Biotechnology - INCOB 2008: programme and abstracts. Vellore (India): School of Biotechnology, Chemical and Biomedical Engineering: Vit University, Vellore. Tamilandu, India. 2008; pp 5-6.
51. Cencic A. EU-WP6 Programme PathogenCombat Annual Report. 2009; www.pathogencombat.com.
52. Langerholc T, Maragkoudakis A, Wollgast J, Gradisnik L, Cencic A. Novel and established intestinal cell line models - an indispensable tool in food science and nutrition. Trends in Food Science and Technology 2011; 22: S11-S20.
53. Heid MI, Henneman P, Hicks A, et al. Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis 2010; 208: 412-20.
54. Ling H, Waterworth DM, Stirnadel HA, et al. Genome-wide linkage and association analyses to indentify genes influencing adiponectin levels: the GEMS study. Obesity 2009; 17: 737-44.